HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by FRANCHI, M. Articles by BOLIS, P. Search for Related Content PubMed PubMed Citation Articles by FRANCHI, M. Articles by BOLIS, P.

Endometrial Thickness in Tamoxifen-Treated Patients: An Independent Predictor of Endometrial Disease

From the Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy.

Address reprint requests to: Massimo Franchi, MD Department of Obstetrics and Gynecology University of Insubria Viale Borri 57 Varese 21100 Italy

Objective: To assess the independent contribution of transvaginal ultrasound in identifying women at risk for endometrial disorders, and determine whether a cutoff value identifies women who need endometrial histologic assessment.

Methods: Postmenopausal women with breast cancer who were receiving tamoxifen, with ultrasonographic endometrial thickness greater than 4 mm or vaginal bleeding, had hysteroscopy with selective endometrial biopsies. Endometrial thickness, duration of tamoxifen therapy, and endometrial histology were studied. Parametric and nonparametric tests and logistic regression and receiver operating characteristic curves were used for statistical analysis.

Results: The study population consisted of 163 women, 46 with vaginal bleeding. The proportion of women with abnormal histologic findings was greater among those with endometrial thicknesses exceeding 9 mm compared with those with endometrial thicknesses 9 mm or less (60% versus 6.1%, P < .001) and among women who received tamoxifen for more than 27 months than those who received it for less time (46% versus 16%, P < .005). Logistic regression showed that endometrial thickness greater than 9 mm and vaginal bleeding were independent predictors of abnormal findings at hysteroscopy.

Conclusion: In women taking tamoxifen, sonographic endometrial thickness exceeding 9 mm and the presence of vaginal bleeding are independent predictors of endometrial disease. If either exists, hysteroscopy and biopsy should be done.

This article has been cited by other articles:

				K. Fong, P. Causer, M. Atri, A. Lytwyn, and R. Kung Transvaginal US and Hysterosonography in Postmenopausal Women with Breast Cancer Receiving Tamoxifen: Correlation with Hysteroscopy and Pathologic Study RadioGraphics, January 1, 2003; 23(1): 137 - 150. [Abstract] [Full Text] [PDF]

				K. Fong, R. Kung, A. Lytwyn, M. Trudeau, W. Chapman, P. Nugent, P. Glanc, L. Manchul, D. Szabunio, and T. Myhr Endometrial Evaluation with Transvaginal US and Hysterosonography in Asymptomatic Postmenopausal Women with Breast Cancer Receiving Tamoxifen Radiology, September 1, 2001; 220(3): 765 - 773. [Abstract] [Full Text] [PDF]

				B. Gerber, A. Krause, H. Muller, T. Reimer, T. Kulz, J. Makovitzky, G. Kundt, and K. Friese Effects of Adjuvant Tamoxifen on the Endometrium in Postmenopausal Women With Breast Cancer: A Prospective Long-Term Study Using Transvaginal Ultrasound J. Clin. Oncol., October 20, 2000; 18(20): 3464 - 3470. [Abstract] [Full Text] [PDF]

				Ultrasound Monitoring Benefits Women Taking Tamoxifen Journal Watch Women's Health, August 1, 1999; 1999(801): 5 - 5. [Full Text]